TGF-β regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Zhang, Qiang ^a   Chen, Lin ^a   Helfand, Brian T ^a   Jang, Thomas L ^b   Sharma, Vidit ^a   Kozlowski, James ^a   Kuzel, Timothy Michael ^a   Zhu, Lihua J ^c   Yang, Ximing J ^a   Javonovic, Borko ^a   Guo, Yinglu ^d   Lonning, Scott ^e   Harper, Jay ^e   Teicher, Beverly A ^e   Brendler, Charles ^f   Yu, Nengwang ^a   Catalona, William J ^a   Lee, Chung ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d PEKING UNIVERSITY FIRST HOSPITAL   (China)

^e GENZYME CORPORATION   (United States)

^f NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; DNA (CYTOSINE 5) METHYLTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GRADING; CANCER INHIBITION; CANCER INVASION; CANCER RECURRENCE; CELL ACTIVITY; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME REGULATION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PREDICTION; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANIMAL; C57BL MOUSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; MALE; METABOLISM; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

MUS;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 80053601066     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025168     Document Type: Article

References (49)

1. Sintich SM, Lamm MLG, Sensibar Jam Lee C, (1999) Transforming growth factor-ß1 induced proliferation of the prostate cancer cell line, TSU-Pr1: the role of platelet-derived growth factor. Endocrinology 140: 3411-3415.
2. Zhou W, Park I, Pins M, Kozlowski JM, Jovanovic B, et al. (2003) Dual regulation of proliferation and growth arrest in prostatic stromal cells by transforming growth factor-ß1. Endocrinology 144: 4280-4284.
3. Pardali K, Moustakas A, (2007) Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 1775: 21-62.
4. Zhang Q, Rubenstein JN, Jang TL, Pins M, Javonovic B, et al. (2005) Insensitivity to transforming growth factor-beta results from promoter methylation of cognate receptors in human prostate cancer cells (LNCaP). Mol Endocrinol 19: 2390-2399.
5. Robertson KD, (2001) DNA methylation, methyltransferases and cancer. Oncogene 20: 3139-3155.
6. Bestor TH, (2000) DNA-methyltransferase of mammals. Hum Mol Genet 9: 2395-2402.
7. Okano M, Bell DW, Haber DA, Li E, (1999) Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99: 247-257.
8. Lu R, Wang X, Chen ZF, Sun DF, Tian XQ, et al. (2007) Inhibition of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway decreases DNA methylation in colon cancer cells. J Biol Chem 282: 12249-12259.
9. Saito Y, Yamazoe T, Qin Z, Ohgomori K, Mochitate K, et al. (2003) Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer 105: 527-532.
10. Etoh T, Kanai Y, Ushijima S, Nakagawa T, Nakanishi Y, et al. (2004) Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol 164: 689-699.
11. Xing J, Stewart DJ, Gu J, Lu C, Spitz MR, et al. (2008) Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer. Br J Cancer 98: 1716-22.
12. Amara K, Ziadi S, Hachana M, Soltani N, Korbi S, et al. (2010) DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B-cell lymphomas. Cancer Sci 101: 1722-1730.
13. Chen MF, Chen WC, Chang YJ, Wu CF, Wu CT, (2010) Role of DNA methyltransferase 1 in hormone-resistant prostate cancer. J Mol Med 88: 953-962.
14. Luo X, Zhang Q, Liu V, Xia Z, Pothoven KL, et al. (2008) Cutting edge: TGF-beta-induced expression of Foxp3 in T cells is mediated through inactivation of ERK. J Immunol 180: 2757-2761.
15. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Lang S, et al. (1996) Loss of expression of transforming growth factor-β receptors type I and type II correlates with tumor grade in human prostate cancer tissues. Clinical Cancer Research 2: 1255-1261.
16. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Sensibar JA, et al. (1996) Genetic change in transforming growth factor-β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells. Can Res 56: 44-48.
17. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, et al. (1996) Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Caner Res 2: 1627-1636.
18. Kozlowski JM, (1988) Prostate cancer and the invasive phenotype: application of new in vivo and in vitro approaches. In: Fidler IJ, Nicholson G, editors. Tumor progression and metastasis New York Alan R Liss Inc pp. 189-231.
19. Kozlowski JM, (1991) Growth requirements of human prostate cancers in vitro and in vivo. In: Rosen S, Lee C, Tallman MS, editors. Innovations in Urologic Oncology: Selected Papers from a Northwestern University Cancer Center Symposium Chicago Precept Press pp. 13-37.
20. Lee C, Shevrin DH, Kozlowski JM, (1993) In vivo and in vitro approaches to study metastasis in human prostatic cancer. Cancer Met Rev 12: 21-28.
21. Zhang Q, Yang X, Pins M, Javonovic B, Kuzel T, et al. (2005) Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res 65: 1761-1769.
22. Zhang Q, Helfand BT, Jang TL, Zhu LJ, Chen L, et al. (2009) Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy. Clin Can Res 15: 3557-3567.
23. Liu VC, Wong LY, Jang T, Shah AH, Park I, et al. (2007) Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 178: 2883-2892.
24. Perry K, Wong L, Liu V, Park I, Zhang Q, et al. (2008) Treatment of transforming growth factor-beta-insensitive mouse Renca tumor by transforming growth factor-beta elimination. Urology 72: 225-229.
25. Zhang Q, Yang XJ, Kundu SD, Pins M, Javonovic B, et al. (2006) Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle. Mol Cancer Ther 5: 1733-1743.
26. Attwood J, Richardson B, (2004) Relative quantitation of DNA methyltransferase mRNA by real-time RT-PCR assay. Methods Mol Biol 287: 273-283.
27. Serganova I, Moroz E, Vider J, Gogiberidze G, Moroz M, et al. (2009) Multimodality imaging of TGFbeta signaling in breast cancer metastases. FASEB J 23: 2662-2672.
28. Ponomarev V, Doubrovin M, Serganova I, Vider J, Shavrin A, et al. (2004) Novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging 31: 740-751.
29. Steg A, Vickers SM, Eloubeidi M, Wang W, Eltoum IA, et al. (2007) Hedgehog pathway expression in heterogeneous pancreatic adenocarcinoma: implications for the molecular analysis of clinically available biopsies. Diagn Mol Pathol 16: 229-237.
30. Grizzle WE, Myers RB, Manne U, Srivastava S, (1998) Immunohistochemical Evaluation of biomarkers in prostate and colorectal neoplasia: Principles and guidelines. In: Hanausek M, Walaszek Z, editors. Methods in Molecular Medicine, Vol 14: Tumor Marker Protocols Humana Press, Inc, Totowa, NJ pp. 143-160.
31. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP, (1998) Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv Cancer Res 72: 141-196.
32. Chan MF, Liang G, Jones PA, (2000) Relationship between transcription and DNA methylation. In: Jones PA, Vogt PK, editors. DNA methylation and cancer New York Springer-Verlag pp. 75-99.
33. Bender CM, Pao MM, Jones PA, (1998) Inhibition of DNA methylation by 5-AZA-2′ deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 58: 95-101.
34. Santi DV, Garrett CE, Barr PJ, (1983) On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs. Cell 33: 9-10.
35. Wu JC, Santi DV, (1987) Kinetic and catalytic mechanism of HhaI methyltransferase. J Biol Chem 262: 4778-4786.
36. Bacolla A, Pradhan S, Roberts RJ, Wells RD, (1999) Recombinant human DNA (cytosine-5) methyltransferase II Steady-state kinetics reveal allosteric activation by methylated DNA. J Biol Chem 274: 33011-33019.
37. Deng C, Lu Q, Zhang Z, Rao T, Attwood J, et al. (2003) Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 48: 746-756.
38. Lu Q, Wu A, Richardson BC, (2005) Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol 174: 6212-6219.
39. Yu N, Wang M, (2008) Anticancer drug discovery targeting DNA hypermethylation. Curr Med Chem 15: 1350-1375.
40. Ghoshal K, Bai S, (2007) DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc) 43: 395-422.
41. Gowher H, Jeltsch A, (2004) Mechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapy. Cancer Biol Ther 3: 1062-1068.
42. Fandy TE, (2009) Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseases. Curr Med Chem 16: 2075-2085.
43. Patra SK, Patra A, Zhao H, Dahiya R, (2002) DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog 33: 163-171.
44. MacLeod AR, Rouleau J, Szyf M, (1995) Regulation of DNA methylation by the Ras signaling pathway. J Biol Chem 270: 11327-11337.
45. Lee MK, Pardoux C, Hall MC, Lee PS, Warburton D, et al. (2007) TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J 26: 3957-67.
46. Giehl K, Seidel B, Gierschik P, Adler G, Menke A, (2000) TGF beta1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation. Oncogene 19: 4531-4541.
47. Lin C, Zhang Q, Helfand B, Qin W, Sharma V, et al. (2010) Erk Activation mediates Transforming Growth Factor-ß-induced up-regulation of DNA methyltransferase in human prostate cancer cells. 101th, American Urological Association Annual Meeting San Francisco, CA AB-1001488.
48. Zhang Q, Chen L, Helfand B, Kozlowski J, Brendler C, et al. (2011) The recruitment of PP2A by TGF-β receptors mediates the response to TGF-β-induced activation of ERK in prostate cancer. 2011 102nd American Association of Cancer Research (AACR) Annual meeting, Orlando, FL. Cancer Research, Late-breaking abstract LB-3.
49. Lin RK, Hsieh YS, Lin P, Hsu HS, Chen CY, et al. (2010) The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J Clin Invest 120: 521-532.